表紙：脂質代謝異常症治療薬市場 - 世界の市場規模、シェア、動向分析、機会、予測（2019年～2029年）

市場調査レポート

商品コード

1391820

脂質代謝異常症治療薬市場 - 世界の市場規模、シェア、動向分析、機会、予測（2019年～2029年）

Lipid Metabolism Disease Drug Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type; By Distribution Channel; By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

出版日: 2023年11月29日 | 発行: Blueweave Consulting

| ページ情報: 英文 400 Pages | 納期: 2～3営業日

価格

Unprintable PDF (Single User License)

USD 4,850 764,020円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストはできません。PDFの印刷はできません。

Unprintable PDF (Group License)

USD 5,750 905,797円

レポートPDFを企業内すべての方がご利用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷はできません。

PDF (Enterprise License)

USD 8,150 1,283,869円

レポートPDFを企業内のすべての方がご利用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷も可能です。データのエクセルが提供されます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.53円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

脂質代謝異常症治療薬の世界市場規模はCAGR 7.1%で大幅に拡大、2029年には244億4,000万米ドルに達する

世界の脂質代謝異常症治療薬市場は、各地域の人々の不健康なライフスタイルに起因する脂質代謝疾患の有病率の増加に対する治療への注目が高まっているため、活況を呈しています。

戦略コンサルティングおよび市場調査会社大手のBlueWeave Consulting社は、最近の調査で、2022年の脂質代謝異常症治療薬の世界市場規模を161億9,000万米ドルと推定しました。BlueWeave社は、2023年～2029年の予測期間中に、脂質代謝異常症治療薬の世界市場規模はCAGR 7.1%の著しい成長を遂げ、2029年には244億4,000万米ドルに達すると予測しています。脂質代謝異常症治療薬の世界市場の主な成長促進要因には、世界の病院や小売薬局を含む様々な用途におけるこれらの医薬品に対する需要の高まりが含まれます。脂質代謝異常症治療薬の世界市場は、企業、事業体、共同事業体などの多様な事業体から構成され、代謝疾患のさまざまな症状に対処する医薬品の開発と流通に取り組んでいます。これには、甲状腺機能亢進症のための抗甲状腺薬とともに、インスリン、プラムリンタイド、その他の糖尿病治療薬の製造が含まれます。世界の脂質代謝異常症治療薬市場には、副甲状腺機能亢進症や甲状腺機能低下症のような代謝性疾患を対象とした抗糖尿病薬や抗甲状腺薬のセグメントを含め、下垂体、副腎、副甲状腺の疾患治療薬も含まれています。しかし、市場の歴史的な軌跡には、政府機関や各国政府による厳しい規制があり、高い治療費に対する批判につながっています。公的ヘルスケア機関や医師への割引価格での医薬品提供義務のために販売課題が浮上し、利益率の低下につながり、市場全体の拡大に影響を与えています。

本レポートの詳細な分析により、世界の脂質代謝異常症治療薬市場の成長可能性、今後の動向、統計に関する情報を提供します。また、総市場規模の予測を促進する要因も取り上げています。当レポートは、世界の脂質代謝異常症治療薬市場の最新技術動向や、意思決定者が戦略的な意思決定を行う際に役立つ業界インサイトを提供することをお約束します。さらに、市場の成長促進要因・課題・競争力についても分析しています。

業界のバリューチェーン分析
DROC分析
- 成長促進要因
  - 脂質代謝疾患の罹患率の増加
  - 不健康なライフスタイルの増加
- 抑制要因
  - 副作用
  - 高コスト
- 機会
  - 高齢人口
  - 医薬品開発の進歩
- 課題
  - 規制上のハードル
  - 競合
技術の進歩/最近の開発
規制の枠組み
ポーターのファイブフォース分析

第4章世界の脂質代謝異常症治療薬市場の概要

市場の種類と予測（2019年～2029年）
- 金額別
市場シェアと予測
- タイプ別
  - 市販薬
  - 処方薬
- 流通チャネル別
  - 病院薬局
  - 小売薬局
  - オンライン薬局
- 地域別
  - 北米
  - 欧州
  - アジア太平洋
  - ラテンアメリカ
  - 中東およびアフリカ

第5章北米の脂質代謝異常症治療薬市場

市場の種類と予測（2019年～2029年）
- 金額別
市場シェアと予測
- タイプ別
- 流通チャネル別
- 国別
  - 米国
  - カナダ

第6章欧州の脂質代謝異常症治療薬市場

市場の種類と予測（2019年～2029年）
- 金額別
市場シェアと予測
- タイプ別
- 流通チャネル別
- 国別
  - ドイツ
  - 英国
  - イタリア
  - フランス
  - スペイン
  - ベルギー
  - ロシア
  - オランダ
  - その他欧州

第7章アジア太平洋の脂質代謝異常症治療薬市場

市場の種類と予測（2019年～2029年）
- 金額別
市場シェアと予測
- タイプ別
- 流通チャネル別
- 国別
  - 中国
  - インド
  - 日本
  - 韓国
  - オーストラリアとニュージーランド
  - インドネシア
  - マレーシア
  - シンガポール
  - ベトナム
  - その他アジア太平洋

第8章ラテンアメリカの脂質代謝異常症治療薬市場

市場の種類と予測（2019年～2029年）
- 金額別
市場シェアと予測
- タイプ別
- 流通チャネル別
- 国別
  - ブラジル
  - メキシコ
  - アルゼンチン
  - ペルー
  - その他ラテンアメリカ

第9章中東・アフリカの脂質代謝異常症治療薬市場

市場の種類と予測（2019年～2029年）
- 金額別
市場シェアと予測
- タイプ別
- 流通チャネル別
- 国別
  - サウジアラビア
  - アラブ首長国連邦
  - カタール
  - クウェート
  - 南アフリカ
  - ナイジェリア
  - アルジェリア
  - その他中東・アフリカ

第10章競合情勢

主要企業とその製品のリスト
世界の脂質代謝異常症治療薬市場シェア分析（2022年）
経営パラメータによる競合ベンチマーキング
主要な戦略的展開（合併、買収、パートナーシップなど）

第11章世界の脂質代謝異常症治療薬市場に対する新型コロナウイルス感染症（COVID-19）の影響

第12章企業プロファイル（会社概要、財務マトリックス、競合情勢、主要人材、主要競合、連絡先住所、戦略的展望、 SWOT分析）

AstraZeneca Plc
Boehringer Ingelheim
Merck KGaA
Novartis AG
Takeda Pharmaceutical Co. Ltd
Eli Lilly
Johnson &Johnson
Bayer
Pfizer
Sanofi
その他の主要企業

第13章主要な戦略的推奨事項

第14章調査手法

図表

List of Figures

Figure 1 Global Lipid Metabolism Disease Drug Segmentation
Figure 2 Global Lipid Metabolism Disease Drug Market Value Chain Analysis
Figure 3 Company Market Share Analysis, 2022
Figure 4 Global Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 5 Global Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 6 Global Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 7 Global Lipid Metabolism Disease Drug Market Share, By Region, By Value, 2019-2029
Figure 8 North America Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 9 North America Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 10 North America Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value,
Figure 11 North America Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
Figure 12 United States Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 13 United States Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 14 United States Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 15 Canada Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 16 Canada Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 17 Canada Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 18 Europe Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 19 Europe Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 20 Europe Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 21 Europe Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
Figure 22 Germany Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 23 Germany Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 24 Germany Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 25 United Kingdom Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 26 United Kingdom Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 27 United Kingdom Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 28 Italy Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 29 Italy Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 30 Italy Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 31 France Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 32 France Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 33 France Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 34 Spain Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 35 Spain Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 36 Spain Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 37 Belgium Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 38 Belgium Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 39 Belgium Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 40 Russia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 41 Russia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 42 Russia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 43 The Netherlands Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 44 The Netherlands Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 45 The Netherlands Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 46 Rest of Europe Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 47 Rest of Europe Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 48 Rest of Europe Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 49 Asia-Pacific Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 50 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 51 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 52 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
Figure 53 China Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 54 China Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 55 China Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 56 India Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 57 India Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 58 India Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 59 Japan Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 60 Japan Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 61 Japan Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 62 South Korea Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 63 South Korea Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 64 South Korea Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 65 Australia & New Zealand Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 66 Australia & New Zealand Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 67 Australia & New Zealand Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 68 Indonesia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 69 Indonesia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 70 Indonesia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 71 Malaysia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 72 Malaysia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 73 Malaysia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 74 Singapore Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 75 Singapore Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 76 Singapore Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 77 Vietnam Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 78 Vietnam Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 79 Vietnam Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 80 Rest of APAC Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 81 Rest of APAC Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 82 Rest of APAC Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 83 Latin America Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 84 Latin America Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 85 Latin America Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 86 Latin America Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
Figure 87 Brazil Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 88 Brazil Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 89 Brazil Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 90 Mexico Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 91 Mexico Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 92 Mexico Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 93 Argentina Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 94 Argentina Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 95 Argentina Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 96 Peru Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 97 Peru Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 98 Peru Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 99 Rest of LATAM Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 100 Rest of LATAM Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 101 Rest of LATAM Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 102 Middle East & Africa Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 103 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 104 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 105 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
Figure 106 Saudi Arabia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 107 Saudi Arabia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 108 Saudi Arabia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 109 UAE Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 110 UAE Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 111 UAE Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 112 Qatar Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 113 Qatar Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 114 Qatar Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 115 Kuwait Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 116 Kuwait Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 117 Kuwait Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 118 South Africa Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 119 South Africa Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 120 South Africa Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 121 Nigeria Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 122 Nigeria Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 123 Nigeria Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 124 Algeria Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 125 Algeria Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 126 Algeria Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Figure 127 Rest of MEA Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Figure 128 Rest of MEA Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Figure 129 Rest of MEA Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029

List of Tables

Table 1 Global Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 2 Global Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 3 Global Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 4 Global Lipid Metabolism Disease Drug Market Share, By Region, By Value, 2019-2029
Table 5 North America Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 6 North America Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 7 North America Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 8 North America Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
Table 9 United States Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 10 United States Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 11 United States Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 12 Canada Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 13 Canada Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 14 Canada Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 15 Europe Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 16 Europe Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 17 Europe Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 18 Europe Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
Table 19 Germany Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 20 Germany Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 21 Germany Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 22 United Kingdom Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 23 United Kingdom Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 24 United Kingdom Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 25 Italy Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 26 Italy Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 27 Italy Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 28 France Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 29 France Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 30 France Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 31 Spain Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 32 Spain Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 33 Spain Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 34 Belgium Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 35 Belgium Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 36 Belgium Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 37 Russia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 38 Russia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 39 Russia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 40 The Netherlands Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 41 The Netherlands Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 42 The Netherlands Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 43 Rest of Europe Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 44 Rest of Europe Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 45 Rest of Europe Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 46 Asia-Pacific Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 47 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 48 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 49 Asia-Pacific Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
Table 50 China Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 51 China Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 52 China Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 53 India Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 54 India Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 55 India Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 56 Japan Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 57 Japan Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 58 Japan Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 59 South Korea Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 60 South Korea Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 61 South Korea Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 62 Australia & New Zealand Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 63 Australia & New Zealand Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 64 Australia & New Zealand Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 65 Indonesia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 66 Indonesia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 67 Indonesia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 68 Malaysia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 69 Malaysia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 70 Malaysia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 71 Singapore Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 72 Singapore Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 73 Singapore Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 74 Vietnam Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 75 Vietnam Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 76 Vietnam Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 77 Rest of APAC Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 78 Rest of APAC Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 79 Rest of APAC Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 80 Latin America Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 81 Latin America Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 82 Latin America Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 83 Latin America Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
Table 84 Brazil Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 85 Brazil Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 86 Brazil Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 87 Mexico Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 88 Mexico Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 89 Mexico Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 90 Argentina Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 91 Argentina Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 92 Argentina Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 93 Peru Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 94 Peru Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 95 Peru Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 96 Rest of LATAM Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 97 Rest of LATAM Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 98 Rest of LATAM Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 99 Middle East & Africa Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 100 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 101 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 102 Middle East & Africa Lipid Metabolism Disease Drug Market Share, By Country, By Value, 2019-2029
Table 103 Saudi Arabia Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 104 Saudi Arabia Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 105 Saudi Arabia Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 106 UAE Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 107 UAE Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 108 UAE Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 109 Qatar Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 110 Qatar Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 111 Qatar Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 112 Kuwait Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 113 Kuwait Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 114 Kuwait Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 115 South Africa Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 116 South Africa Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 117 South Africa Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 118 Nigeria Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 119 Nigeria Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 120 Nigeria Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 121 Algeria Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 122 Algeria Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 123 Algeria Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029
Table 124 Rest of MEA Lipid Metabolism Disease Drug Market Type, By Value (USD Billion), 2019-2029
Table 125 Rest of MEA Lipid Metabolism Disease Drug Market Share, By Type, By Value, 2019-2029
Table 126 Rest of MEA Lipid Metabolism Disease Drug Market Share, By Distribution Channel, By Value, 2019-2029Table 207 Alnylam Pharmaceuticals Company Overview
Table 126 AstraZeneca Plc Company Overview
Table 127 AstraZeneca Plc Financial Overview
Table 128 Boehringer Ingelheim Company Overview
Table 129 Boehringer Ingelheim Financial Overview
Table 130 Merck KGaA Company Overview
Table 131 Merck KGaA Financial Overview
Table 132 Novartis AG Company Overview
Table 133 Novartis AG Financial Overview
Table 134 Takeda Pharmaceutical Co. Ltd Company Overview
Table 135 Takeda Pharmaceutical Co. Ltd Financial Overview
Table 136 Eli Lilly Company Overview
Table 137 Eli Lilly Financial Overview
Table 138 Johnson & Johnson Company Overview
Table 139 Johnson & Johnson Financial Overview
Table 140 Bayer Company Overview
Table 141 Bayer Financial Overview
Table 142 Pfizer Company Overview
Table 143 Pfizer Financial Overview
Table 144 Sanofi Company Overview
Table 145 Sanofi Financial Overview

Product Code: BWC23975

Global Lipid Metabolism Disease Drug Market Size Expands at Significant CAGR of 7.1% to Reach USD 24.44 Billion by 2029.

Global lipid metabolism disease drug market is flourishing because of an increasing focus on the treatment of growing prevalence of lipid metabolism diseases driven by unhealthy lifestyle among people across the regions.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Lipid Metabolism Disease Drug Market size at USD 16.19 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the Global Lipid Metabolism Disease Drug Market size to grow at a significant CAGR of 7.1% reaching a value of USD 24.44 billion by 2029. Major growth drivers for the Global Lipid Metabolism Disease Drug Market include a rising demand for these drugs in various applications, including hospitals and retail pharmacies globally. The Global Lipid Metabolism Disease Drug Market comprises diverse entities, such as companies, proprietorships, and collaborations, committed to developing and distributing medications addressing a range of conditions within metabolic disorders. This involves producing insulin, pramlintide, and other diabetes drugs, along with anti-thyroid medications for hyperthyroidism. The Global Lipid Metabolism Disease Drug Market also encompasses medications for disorders in the pituitary, adrenal, and parathyroid glands, including segments for anti-diabetic and anti-thyroid drugs targeting metabolic diseases like hyperparathyroidism and hypopituitarism. However, the market's historical trajectory is marked by strict regulations from governmental bodies and national governments, leading to criticisms of high treatment costs. Sales challenges have emerged due to obligations to offer medications to public healthcare institutions and physicians at discounted rates, leading to reduced profit margins and impacting the market's overall expansion.

Impact of Geopolitical Tensions on the Global Lipid Metabolism Disease Drug Market

The Global Lipid Metabolism Disease Drug Market has been significantly impacted by intensifying geopolitical tensions in recent times. For instance, the ongoing Russia's war on Ukraine has disrupted supply chains and hindered the production and distribution of pharmaceuticals, affecting the availability of lipid metabolism disease drugs. In addition, the sanctions imposed on Russia by the United States and other countries can limit the movement of essential medical resources, leading to potential shortages. The turmoil has far-reaching consequences on healthcare measures in Ukraine and across the regions, exacerbating the demand for medicines, depleting inventories, and creating logistical obstacles for resupplying critical medical resources. Meanwhile, calls for economic disengagement from Russia by pharmaceutical industry leaders may affect investments and influence healthcare budgets, ultimately affecting patient affordability and the demand for lipid metabolism disease drugs. Beyond the conflict in Ukraine, collaborative research efforts and international partnerships vital for drug development may face strain, potentially slowing down innovations in the field. In essence, these geopolitical tensions introduce uncertainties and challenges across various dimensions of the lipid metabolism disease drug market, emphasizing the need for strategic adaptation and resilience in navigating these complex circumstances.

Despite the current challenges posed by geopolitical tensions, there are potential growth opportunities for the global lipid metabolism disease drug market. The heightened awareness of the vulnerabilities in the pharmaceutical supply chain due to escalating and spreading geopolitical tensions could drive industry stakeholders to invest in more resilient and diversified supply chain models. Innovations in telehealth and digital health solutions may emerge as a response to disruptions in traditional healthcare delivery systems, providing new avenues for patient access and engagement. Also, an increased focus on R&D to address the unique health challenges arising from geopolitical conflicts could lead to the discovery and development of novel therapeutic approaches and drug formulations.

Global Lipid Metabolism Disease Drug Market - By Distribution Channel

Based on distribution channel, the Global Lipid Metabolism Disease Drug Market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The online pharmacies segment holds the highest share in the global lipid metabolism disease drug market by distribution channel. Online pharmacies offer convenient access to a wide range of medications for lipid metabolism diseases, allowing patients to order prescriptions from the comfort of their homes. The ease of online transactions, doorstep delivery, and the ability to compare prices contribute to the segment's high market share. Additionally, the growing preference for virtual consultations and the expansion of e-commerce platforms further bolster the prominence of online pharmacies in distributing lipid metabolism disease drugs globally.

Global Lipid Metabolism Disease Drug Market - By Region

The in-depth research report on The Global Lipid Metabolism Disease Drug Market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Asia Pacific region dominates the global lipid metabolism disease drug market. It can be primarily due to the rising number of teenagers, leading to a higher prevalence of unhealthy lifestyles. This contributes to increased instances of obesity and heart diseases associated with elevated levels of bad cholesterol and unhealthy fats. The region's substantial demand for lipid metabolism disease drugs is a result of these prevalent health challenges, establishing the Asia Pacific as a pivotal market. Moreover, evolving dietary habits and a growing middle class population further underscore the market's importance in addressing lipid metabolism diseases in this region.

Competitive Landscape

Major players operating in the Global Lipid Metabolism Disease Drug market include: AstraZeneca Plc, Boehringer Ingelheim, Merck KGaA, Novartis AG, Takeda Pharmaceutical Co. Ltd, Eli Lilly, Johnson & Johnson, Bayer, Pfizer, and Sanofi. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Lipid Metabolism Disease Drug Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Lipid Metabolism Disease Drug Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Executive Summary

3. Global Lipid Metabolism Disease Drug Market Insights

3.1. Industry Value Chain Analysis
3.2. DROC Analysis
- 3.2.1. Growth Drivers
  - 3.2.1.1. Increasing prevalence of lipid metabolism diseases
  - 3.2.1.2. Increasing adoption of an unhealthy lifestyle
- 3.2.2. Restraints
  - 3.2.2.1. Side effects
  - 3.2.2.2. High costs
- 3.2.3. Opportunities
  - 3.2.3.1. Aging population
  - 3.2.3.2. Advancements in drug development
- 3.2.4. Challenges
  - 3.2.4.1. Regulatory hurdles
  - 3.2.4.2. Competition
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry

4. Global Lipid Metabolism Disease Drug Market Overview

4.1. Market Type & Forecast, 2019-2029
- 4.1.1. By Value (USD Billion)
4.2. Market Share and Forecast
- 4.2.1. By Type
  - 4.2.1.1. OTC
  - 4.2.1.2. Rx Drugs
- 4.2.2. By Distribution Channel
  - 4.2.2.1. Hospital pharmacies
  - 4.2.2.2. Retail pharmacies
  - 4.2.2.3. Online pharmacies
- 4.2.3. By Region
  - 4.2.3.1. North America
  - 4.2.3.2. Europe
  - 4.2.3.3. Asia Pacific (APAC)
  - 4.2.3.4. Latin America (LATAM)
  - 4.2.3.5. Middle East and Africa (MEA)

5. North America Lipid Metabolism Disease Drug Market

5.1. Market Type & Forecast, 2019-2029
- 5.1.1. By Value (USD Billion)
5.2. Market Share & Forecast
- 5.2.1. By Type
- 5.2.2. By Distribution Channel
- 5.2.3. By Country
  - 5.2.3.1. United States
  - 5.2.3.1.1. By Type
  - 5.2.3.1.2. By Distribution Channel
  - 5.2.3.2. Canada
  - 5.2.3.2.1. By Type
  - 5.2.3.2.2. By Distribution Channel

6. Europe Lipid Metabolism Disease Drug Market

6.1. Market Type & Forecast, 2019-2029
- 6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Distribution Channel
- 6.2.3. By Country
  - 6.2.3.1. Germany
  - 6.2.3.1.1. By Type
  - 6.2.3.1.2. By Distribution Channel
  - 6.2.3.2. United Kingdom
  - 6.2.3.2.1. By Type
  - 6.2.3.2.2. By Distribution Channel
  - 6.2.3.3. Italy
  - 6.2.3.3.1. By Type
  - 6.2.3.3.2. By Distribution Channel
  - 6.2.3.4. France
  - 6.2.3.4.1. By Type
  - 6.2.3.4.2. By Distribution Channel
  - 6.2.3.5. Spain
  - 6.2.3.5.1. By Type
  - 6.2.3.5.2. By Distribution Channel
  - 6.2.3.6. Belgium
  - 6.2.3.6.1. By Type
  - 6.2.3.6.2. By Distribution Channel
  - 6.2.3.7. Russia
  - 6.2.3.7.1. By Type
  - 6.2.3.7.2. By Distribution Channel
  - 6.2.3.8. The Netherlands
  - 6.2.3.8.1. By Type
  - 6.2.3.8.2. By Distribution Channel
  - 6.2.3.9. Rest of Europe
  - 6.2.3.9.1. By Type
  - 6.2.3.9.2. By Distribution Channel

7. Asia-Pacific Lipid Metabolism Disease Drug Market

7.1. Market Type & Forecast, 2019-2029
- 7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Distribution Channel
- 7.2.3. By Country
  - 7.2.3.1. China
  - 7.2.3.1.1. By Type
  - 7.2.3.1.2. By Distribution Channel
  - 7.2.3.2. India
  - 7.2.3.2.1. By Type
  - 7.2.3.2.2. By Distribution Channel
  - 7.2.3.3. Japan
  - 7.2.3.3.1. By Type
  - 7.2.3.3.2. By Distribution Channel
  - 7.2.3.4. South Korea
  - 7.2.3.4.1. By Type
  - 7.2.3.4.2. By Distribution Channel
  - 7.2.3.5. Australia & New Zealand
  - 7.2.3.5.1. By Type
  - 7.2.3.5.2. By Distribution Channel
  - 7.2.3.6. Indonesia
  - 7.2.3.6.1. By Type
  - 7.2.3.6.2. By Distribution Channel
  - 7.2.3.7. Malaysia
  - 7.2.3.7.1. By Type
  - 7.2.3.7.2. By Distribution Channel
  - 7.2.3.8. Singapore
  - 7.2.3.8.1. By Type
  - 7.2.3.8.2. By Distribution Channel
  - 7.2.3.9. Vietnam
  - 7.2.3.9.1. By Type
  - 7.2.3.9.2. By Distribution Channel
  - 7.2.3.10. Rest of APAC
  - 7.2.3.10.1. By Type
  - 7.2.3.10.2. By Distribution Channel

8. Latin America Lipid Metabolism Disease Drug Market

8.1. Market Type & Forecast, 2019-2029
- 8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Distribution Channel
- 8.2.3. By Country
  - 8.2.3.1. Brazil
  - 8.2.3.1.1. By Type
  - 8.2.3.1.2. By Distribution Channel
  - 8.2.3.2. Mexico
  - 8.2.3.2.1. By Type
  - 8.2.3.2.2. By Distribution Channel
  - 8.2.3.3. Argentina
  - 8.2.3.3.1. By Type
  - 8.2.3.3.2. By Distribution Channel
  - 8.2.3.4. Peru
  - 8.2.3.4.1. By Type
  - 8.2.3.4.2. By Distribution Channel
  - 8.2.3.5. Rest of LATAM
  - 8.2.3.5.1. By Type
  - 8.2.3.5.2. By Distribution Channel

9. Middle East and Africa Lipid Metabolism Disease Drug Market

9.1. Market Type & Forecast, 2019-2029
- 9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Distribution Channel
- 9.2.3. By Country
  - 9.2.3.1. Saudi Arabia
  - 9.2.3.1.1. By Type
  - 9.2.3.1.2. By Distribution Channel
  - 9.2.3.2. UAE
  - 9.2.3.2.1. By Type
  - 9.2.3.2.2. By Distribution Channel
  - 9.2.3.3. Qatar
  - 9.2.3.3.1. By Type
  - 9.2.3.3.2. By Distribution Channel
  - 9.2.3.4. Kuwait
  - 9.2.3.4.1. By Type
  - 9.2.3.4.2. By Distribution Channel
  - 9.2.3.5. South Africa
  - 9.2.3.5.1. By Type
  - 9.2.3.5.2. By Distribution Channel
  - 9.2.3.6. Nigeria
  - 9.2.3.6.1. By Type
  - 9.2.3.6.2. By Distribution Channel
  - 9.2.3.7. Algeria
  - 9.2.3.7.1. By Type
  - 9.2.3.7.2. By Distribution Channel
  - 9.2.3.8. Rest of MEA
  - 9.2.3.8.1. By Type
  - 9.2.3.8.2. By Distribution Channel

10. Competitive Landscape

10.1. List of Key Players and Their Offerings
10.2. Global Lipid Metabolism Disease Drug Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Lipid Metabolism Disease Drug Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

12.1. AstraZeneca Plc
12.2. Boehringer Ingelheim
12.3. Merck KGaA
12.4. Novartis AG
12.5. Takeda Pharmaceutical Co. Ltd
12.6. Eli Lilly
12.7. Johnson & Johnson
12.8. Bayer
12.9. Pfizer
12.10. Sanofi
12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

14.1. Qualitative Research
- 14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
- 14.3.1. Secondary Research
- 14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations

*Financial information of case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

脂質代謝異常症治療薬市場 - 世界の市場規模、シェア、動向分析、機会、予測（2019年～2029年）

Lipid Metabolism Disease Drug Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type; By Distribution Channel; By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

脂質代謝異常症治療薬の世界市場規模はCAGR 7.1%で大幅に拡大、2029年には244億4,000万米ドルに達する

目次

第1章調査の枠組み

第2章エグゼクティブサマリー

第3章世界の脂質代謝異常症治療薬市場に関する洞察

第4章世界の脂質代謝異常症治療薬市場の概要

第5章北米の脂質代謝異常症治療薬市場

第6章欧州の脂質代謝異常症治療薬市場

第7章アジア太平洋の脂質代謝異常症治療薬市場

第8章ラテンアメリカの脂質代謝異常症治療薬市場

第9章中東・アフリカの脂質代謝異常症治療薬市場

第10章競合情勢

第11章世界の脂質代謝異常症治療薬市場に対する新型コロナウイルス感染症（COVID-19）の影響

第12章企業プロファイル（会社概要、財務マトリックス、競合情勢、主要人材、主要競合、連絡先住所、戦略的展望、 SWOT分析）

第13章主要な戦略的推奨事項

第14章調査手法

List of Figures

List of Tables

Global Lipid Metabolism Disease Drug Market Size Expands at Significant CAGR of 7.1% to Reach USD 24.44 Billion by 2029.

Impact of Geopolitical Tensions on the Global Lipid Metabolism Disease Drug Market

Global Lipid Metabolism Disease Drug Market - By Distribution Channel

Global Lipid Metabolism Disease Drug Market - By Region

Competitive Landscape

Table of Contents

1. Research Framework

2. Executive Summary

3. Global Lipid Metabolism Disease Drug Market Insights

4. Global Lipid Metabolism Disease Drug Market Overview

5. North America Lipid Metabolism Disease Drug Market

6. Europe Lipid Metabolism Disease Drug Market

7. Asia-Pacific Lipid Metabolism Disease Drug Market

8. Latin America Lipid Metabolism Disease Drug Market

9. Middle East and Africa Lipid Metabolism Disease Drug Market

10. Competitive Landscape

11. Impact of Covid-19 on Global Lipid Metabolism Disease Drug Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

13. Key Strategic Recommendations

14. Research Methodology

脂質代謝異常症治療薬市場 - 世界の市場規模、シェア、動向分析、機会、予測（2019年～2029年）

Lipid Metabolism Disease Drug Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type; By Distribution Channel; By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

脂質代謝異常症治療薬の世界市場規模はCAGR 7.1%で大幅に拡大、2029年には244億4,000万米ドルに達する

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の脂質代謝異常症治療薬市場に関する洞察

第4章 世界の脂質代謝異常症治療薬市場の概要

第5章 北米の脂質代謝異常症治療薬市場

第6章 欧州の脂質代謝異常症治療薬市場

第7章 アジア太平洋の脂質代謝異常症治療薬市場

第8章 ラテンアメリカの脂質代謝異常症治療薬市場

第9章 中東・アフリカの脂質代謝異常症治療薬市場

第10章 競合情勢

第11章 世界の脂質代謝異常症治療薬市場に対する新型コロナウイルス感染症（COVID-19）の影響

第12章 企業プロファイル（会社概要、財務マトリックス、競合情勢、主要人材、主要競合、連絡先住所、戦略的展望、 SWOT分析）

第13章 主要な戦略的推奨事項

第14章 調査手法

List of Figures

List of Tables

Global Lipid Metabolism Disease Drug Market Size Expands at Significant CAGR of 7.1% to Reach USD 24.44 Billion by 2029.

Impact of Geopolitical Tensions on the Global Lipid Metabolism Disease Drug Market

Global Lipid Metabolism Disease Drug Market - By Distribution Channel

Global Lipid Metabolism Disease Drug Market - By Region

Competitive Landscape

Table of Contents

1. Research Framework

2. Executive Summary

3. Global Lipid Metabolism Disease Drug Market Insights

4. Global Lipid Metabolism Disease Drug Market Overview

5. North America Lipid Metabolism Disease Drug Market

6. Europe Lipid Metabolism Disease Drug Market

7. Asia-Pacific Lipid Metabolism Disease Drug Market

8. Latin America Lipid Metabolism Disease Drug Market

9. Middle East and Africa Lipid Metabolism Disease Drug Market

10. Competitive Landscape

11. Impact of Covid-19 on Global Lipid Metabolism Disease Drug Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

13. Key Strategic Recommendations

14. Research Methodology

第1章調査の枠組み

第2章エグゼクティブサマリー

第3章世界の脂質代謝異常症治療薬市場に関する洞察

第4章世界の脂質代謝異常症治療薬市場の概要

第5章北米の脂質代謝異常症治療薬市場

第6章欧州の脂質代謝異常症治療薬市場

第7章アジア太平洋の脂質代謝異常症治療薬市場

第8章ラテンアメリカの脂質代謝異常症治療薬市場

第9章中東・アフリカの脂質代謝異常症治療薬市場

第10章競合情勢

第11章世界の脂質代謝異常症治療薬市場に対する新型コロナウイルス感染症（COVID-19）の影響

第12章企業プロファイル（会社概要、財務マトリックス、競合情勢、主要人材、主要競合、連絡先住所、戦略的展望、 SWOT分析）

第13章主要な戦略的推奨事項

第14章調査手法